Skip to main navigation

Prime Medicine Logo

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Sec filings
IR Resources

Press Releases

Year

May 10, 2024

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

May 1, 2024

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

April 29, 2024

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

April 23, 2024

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

March 1, 2024

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

February 28, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

February 20, 2024

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 14, 2024

Prime Medicine Announces Pricing of Upsized Public Offering

February 14, 2024

Prime Medicine Announces Proposed Public Offering of Common Stock

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 25

Print Page

Email Alerts

RSS Feeds

Contact IR

prime_

Site - Footer Bottom

Contact Us
Privacy Policy
Terms of Use

© 2021-2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE and the Prime Medicine logos are trademarks of Prime Medicine, Inc.